# Studies to Gain Insight How the Drugs PCSK9-inhibitors and Statins Affect Cholesterol and Bile Acid Metabolism

> **NCT06140095** · EARLY_PHASE1 · UNKNOWN · sponsor: **Region Stockholm** · enrollment: 8 (estimated)

## Conditions studied

- Acute Metabolic Effects of Evolocumab and Atorvastatin

## Interventions

- **DRUG:** Evolocumab

## Key facts

- **NCT ID:** NCT06140095
- **Lead sponsor:** Region Stockholm
- **Sponsor class:** OTHER_GOV
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2024-02
- **Primary completion:** 2025-12
- **Final completion:** 2025-12
- **Target enrollment:** 8 (ESTIMATED)
- **Last updated:** 2023-11-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06140095

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06140095, "Studies to Gain Insight How the Drugs PCSK9-inhibitors and Statins Affect Cholesterol and Bile Acid Metabolism". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06140095. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*